2011-04-14-世界卫生组织-Fourth_report_of_the_Strategic_and_Technical_Advisory_Group_for_Neglected_Tropical_Diseases_STAG-NTDs_10页_64kb

WHO Strategic and Technical Advisory Group (STAG) Meeting Summary

Date: April 12–13, 2011, Geneva, Switzerland

1. Key Challenges in NTD Control

• Progress: Achievements in NTD control include dracunculiasis eradication, preventive chemotherapy (e.g., schistosomiasis), and vector management.
• Challenges:
  • Shortage of essential medicines (e.g., praziquantel, benznidazole).
  • Poor quality of drugs in some regions and inadequate regulatory oversight.
  • Expanded access to needed medicines not assured.

2. Drug Monitoring Workgroups

• Drug Efficacy: Subgroups focus on measuring drug effectiveness in field conditions.
  • Benzimidazoles, ivermectin, praziquantel, and kinetoplastid drugs with standardized protocols.
  • Concerns about resistance (e.g., Schistosoma species) and need for surveillance.
• Monitoring & Evaluation: Subgroups work on improving tools for field data and impact assessments.

3. Access to Essential Medicines

• Praziquantel Gap: 50 million tablets short in procurement and availability.
• Quality Issues: 67.7% of sampled NTD drugs failed WHO quality standards. Albendazole and mebendazole predominantly implicated.
• Recommendations:
  • Strengthen quality assurance systems for donated medicines.
  • Revise WHO pharmacopoeia standards (e.g., dissolution tests).

4. Roadmap Implementation

• Draft Roadmap: Approved with minor edits; targets set for progress milestones.
• Global Coordination: WHO recommended oversight in dengue control and stock coordination for praziquantel.

5. Final Recommendations

• Develop lab networks and technical capacity for drug monitoring.
• Advocate for better access to key medicines (benznidazole, liposomal amphotericin B).
• Expand prequalification of non-chemotherapy essential medicines.
• Continuously monitor and improve standards for deworming programs.
• Harmonize M&E tools and impact assessment frameworks.
• Address cross-border collaboration in dengue and expanded zoonotic disease control.

Annex Overview

• Annex 1: List of participating institutions and officials.
• Annex 2: Detailed meeting agenda by day.